UA113726U - Фармацевтична композиція "спектран" - Google Patents
Фармацевтична композиція "спектран" Download PDFInfo
- Publication number
- UA113726U UA113726U UAU201608534U UAU201608534U UA113726U UA 113726 U UA113726 U UA 113726U UA U201608534 U UAU201608534 U UA U201608534U UA U201608534 U UAU201608534 U UA U201608534U UA 113726 U UA113726 U UA 113726U
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutical composition
- amoxicillin
- spectran
- animals
- antibiotic
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 34
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims abstract description 26
- 229960003022 amoxicillin Drugs 0.000 claims abstract description 22
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000003115 biocidal effect Effects 0.000 claims abstract description 15
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 12
- 239000003470 adrenal cortex hormone Substances 0.000 claims abstract description 9
- 238000002347 injection Methods 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000003246 corticosteroid Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims abstract description 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 229960001102 betamethasone dipropionate Drugs 0.000 claims description 5
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims description 5
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 claims description 4
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 229960004920 amoxicillin trihydrate Drugs 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 claims description 2
- 229940063655 aluminum stearate Drugs 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- -1 compatible Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 30
- 239000003814 drug Substances 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 241000282326 Felis catus Species 0.000 description 19
- 229940079593 drug Drugs 0.000 description 17
- 208000006311 Pyoderma Diseases 0.000 description 15
- 244000005700 microbiome Species 0.000 description 13
- 208000003251 Pruritus Diseases 0.000 description 11
- 230000007803 itching Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000002489 hematologic effect Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 206010020565 Hyperaemia Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000877 morphologic effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000721 bacterilogical effect Effects 0.000 description 4
- 229960002537 betamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 229940124307 fluoroquinolone Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010037888 Rash pustular Diseases 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000029561 pustule Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- 206010040799 Skin atrophy Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 2
- 229960001907 nitrofurazone Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010023125 Jarisch-Herxheimer reaction Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201608534U UA113726U (xx) | 2016-08-03 | 2016-08-03 | Фармацевтична композиція "спектран" |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201608534U UA113726U (xx) | 2016-08-03 | 2016-08-03 | Фармацевтична композиція "спектран" |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA113726U true UA113726U (xx) | 2017-02-10 |
Family
ID=58049055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201608534U UA113726U (xx) | 2016-08-03 | 2016-08-03 | Фармацевтична композиція "спектран" |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA113726U (xx) |
-
2016
- 2016-08-03 UA UAU201608534U patent/UA113726U/uk unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nielsen et al. | Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs | |
| JP6779619B2 (ja) | 乳房炎をはじめとする微生物感染を処置する方法 | |
| JP2009526765A (ja) | 抗菌物質を含有する局所用組成物 | |
| KR20150119007A (ko) | 국소 미생물 감염의 치료방법 | |
| US11324715B2 (en) | Bismuth-thiol compositions and methods for treating wounds | |
| CN104114166A (zh) | 包含dgla、15-ohepa和/或15-hetre的抗微生物组合物及其使用方法 | |
| CN112245438B (zh) | 一种抗细菌组合物及其复方马波沙星喷剂和制备方法 | |
| Norrby et al. | Clinical and pharmacokinetic studies on cefuroxime | |
| WO2021006317A1 (ja) | プロトテカ症の新規治療剤 | |
| Schifferli et al. | Pharmacokinetics of oxytetracycline and therapeutic implications in veal calves | |
| Cohen et al. | Bacterial eradication by clinafloxacin, CI-990, and ciprofloxacin employing MBC test, in-vitro time-kill and in-vivo time-kill studies. | |
| PT1656143E (pt) | Nova utilização de antibióticos de quinolona | |
| WO2000050019A2 (de) | VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-λB THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN | |
| UA113726U (xx) | Фармацевтична композиція "спектран" | |
| Vogt et al. | Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris | |
| KR101347236B1 (ko) | 동물용 복합 항생제 조성물 | |
| KR102203849B1 (ko) | 동물용 복합 항생제 조성물 | |
| JP2006513188A (ja) | ベンゾキノリンジカルボン酸抗菌薬の組成物 | |
| Kiss et al. | New combination for the therapy of canine otitis externa II Efficacy in vitro and in vivo | |
| CN109045044B (zh) | 一种复方药剂及其制备方法、用途 | |
| WO2002022147A1 (en) | Antibacterial combination comprising neem plant extract | |
| RU2436570C1 (ru) | Способ лечения эндометритов бактериально-микозной этиологии у коров | |
| RU2706115C1 (ru) | Противогрибковое и антимикробное средство комплексного действия | |
| RU2392932C2 (ru) | Средство для лечения кожи воспалительной и аллергической этиологии у кошек и собак "стоп-зуд-2" | |
| Lachguer et al. | Pharmacokinetic disposition of marbofloxacin and danofloxacin in camel (Camelus dromedarius) |